US20030180316A1 - Multivalent vaccine composition - Google Patents
Multivalent vaccine composition Download PDFInfo
- Publication number
- US20030180316A1 US20030180316A1 US10/312,090 US31209003A US2003180316A1 US 20030180316 A1 US20030180316 A1 US 20030180316A1 US 31209003 A US31209003 A US 31209003A US 2003180316 A1 US2003180316 A1 US 2003180316A1
- Authority
- US
- United States
- Prior art keywords
- capsular polysaccharide
- immunogenic composition
- pneumoniae serotype
- group
- meningitidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 229940031348 multivalent vaccine Drugs 0.000 title abstract description 5
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 153
- 239000005017 polysaccharide Substances 0.000 claims abstract description 153
- 150000004676 glycans Chemical class 0.000 claims abstract description 151
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 37
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 34
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract description 33
- 102000036639 antigens Human genes 0.000 claims abstract description 30
- 108091007433 antigens Proteins 0.000 claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 29
- 239000002671 adjuvant Substances 0.000 claims abstract description 22
- 230000001580 bacterial effect Effects 0.000 claims abstract description 20
- 229960003983 diphtheria toxoid Drugs 0.000 claims abstract description 20
- 239000004411 aluminium Substances 0.000 claims abstract description 16
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 201000005702 Pertussis Diseases 0.000 claims abstract description 9
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 6
- 229960005486 vaccine Drugs 0.000 claims description 69
- 230000002163 immunogen Effects 0.000 claims description 47
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 22
- 101710188053 Protein D Proteins 0.000 claims description 22
- 101710132893 Resolvase Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 102000014914 Carrier Proteins Human genes 0.000 claims description 19
- 108010078791 Carrier Proteins Proteins 0.000 claims description 19
- 241000588832 Bordetella pertussis Species 0.000 claims description 17
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 11
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 10
- 241000193449 Clostridium tetani Species 0.000 claims description 9
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims description 9
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000004224 protection Effects 0.000 claims description 8
- 230000005847 immunogenicity Effects 0.000 claims description 7
- 159000000013 aluminium salts Chemical group 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000002480 immunoprotective effect Effects 0.000 claims description 5
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 2
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 claims description 2
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 claims description 2
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 claims description 2
- 101710183389 Pneumolysin Proteins 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 18
- 229940124885 Hiberix Drugs 0.000 description 11
- 108700020122 Hiberix Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 4
- 229940001007 aluminium phosphate Drugs 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108010021711 pertactin Proteins 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- -1 1-cyano-dimethylaminopyridinium tetrafluoroborate Chemical compound 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100521383 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prp-5 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000003497 anti-pneumococcal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940014135 meningitis vaccine Drugs 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000000625 opsonophagocytic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to new combination vaccine formulations.
- Combination vaccines which provide protection against multiple pathogens
- the well-documented phenomenon of antigenic competition (or interference) complicates the development of multi-component vaccines.
- Antigenic interference refers to the observation that administering multiple antigens often results in a diminished response to certain antigens relative to the immune response observed when such antigens are administered individually.
- Combination vaccines are known which can prevent Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae , and optionally Hepatitis B virus and/or Haemophilus influenzae type b (see, for instance, WO 93/24148 and WO 97/00697).
- the present invention concerns the manufacture of the most ambitious multi-valent vaccines to date, the administration of which can prevent or treat infection by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae , Hepatitis B virus, Haemophilus influenzae and N. meningitidis , and preferably also Hepatitis A virus and/or Polio virus, wherein the components of the vaccine do not significantly interfere with the immunological performance of any one component of the vaccine.
- the present invention provides a multi-valent immunogenic composition for conferring protection in a host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae , Hepatitis B virus, Haemophilus influenzae and N. meningitidis comprising:
- Hepatitis B surface antigen HepB
- a carrier protein selected from the group N. meningitidis type A (MenA) and N. meningitidis type C (MenC).
- TT tetanus toxoid
- TT is preferably produced by purification of the toxin from a culture of Clostridium tetani followed by chemical detoxification, but is alternatively made by purification of a recombinant, or genetically detoxified analogue of the toxin (for example, as described in EP 209281).
- Tetanus toxoid also encompasses immunogenic fragments of the fill-length protein (for instance Fragment C—see EP 478602).
- DT diphtheria toxoid
- DT is preferably produced by purification of the toxin from a culture of Corynebacterium diphtheriae followed by chemical detoxification, but is alternatively made by purification of a recombinant, or genetically detoxified analogue of the toxin (for example, CRM197, or other mutants as described in U.S. Pat. Nos. 4,709,017, 5,843,711, 5,601,827, and 5,917,017).
- Acellular pertussis components are well known in the art. Examples include pertussis toxoid (PT), filamentous haemagluttinin (FHA), pertactin (PRN) and agglutinogens 2 and 3. These antigens are partially or highly purified. Preferably 2 or more acellular pertussis components are used in the vaccine. More preferably 2, 3, 4 or all 5 of the above example acellular pertussis components are incorporated in the vaccine. Most preferably PT, FHA and PRN are included. PT may be produced by a variety of manners, for instance by purification of the toxin from a culture of B. pertussis followed by chemical detoxification, or alternatively by purification of a genetically detoxified analogue of PT (for example, as described in U.S. Pat. No. 5,085,862).
- the bacterial capsular polysaccharide conjugates may comprise any carrier peptide, polypeptide or protein comprising at least one T-helper epitope.
- the carrier protein(s) used is selected from the group comprising: tetanus toxoid, diphtheria toxoid, CRM197, recombinant diphtheria toxin (as described in any of U.S. Pat. No. 4,709,017, WO 93/25210, WO 95/33481, or WO 00/48638), pneumolysin (preferably chemically detoxified, or a detoxified mutant) from S. pneumoniae , OMPC from N. meningitidis , and protein D (PD) from H.
- the polysaccharide antigens contained therein are conjugated to more than one carrier.
- (n ⁇ 1) of the polysaccharides could be carried (separately) on one type of carrier, and 1 on a different carrier, or (n ⁇ 2) on one, and 2 on two different carriers, etc.
- 1, 2 or all four could be conjugated to different carriers).
- Protein D is advantageously used as a carrier in the compositions of the invention as it may be used for various (2, 3, 4 or more) polysaccharides in a composition without a marked carrier suppression effect. Most preferably Hib is present as a TT conjugate, and MenA, MenC, MenY and MenW are either TT or PD conjugates. Protein D is also a useful carrier as it provides a further antigen which can provide protection against H influenzae.
- the polysaccharide may be linked to the carrier protein by any known method (for example, by Likhite, U.S. Pat. No. 4,372,945 and by Armor et al., U.S. Pat. No. 4,474,757).
- CDAP conjugation is carried out (WO 95/08348).
- the cyanylating reagent 1-cyano-dimethylaminopyridinium tetrafluoroborate (CDAP) is preferably used for the synthesis of polysaccharide-protein conjugates.
- the cyanilation reaction can be performed under relatively mild conditions, which avoids hydrolysis of the alkaline sensitive polysaceharides. This synthesis allows direct coupling to a carrier protein.
- the above immunogenic composition may further comprise one, two, three, four, five, six or seven components selected from the following list: N. meningitidis type Y polysaccharide [MenY] (preferably conjugated), N. meningitidis type W polysaccharide [MenW] (preferably conjugated), the Vi polysaccharide of Salmonella typhi, N. meningitidis (preferably serotype B) outer membrane vesicles, one or more N.
- N. meningitidis type Y polysaccharide [MenY] preferably conjugated
- N. meningitidis type W polysaccharide [MenW] preferably conjugated
- the Vi polysaccharide of Salmonella typhi preferably serotype B
- N. meningitidis preferably serotype B
- meningitidis preferably serotype B
- outer membrane surface-exposed proteins
- killed attenuated Hepatitis A virus (HepA—preferably the product known as ‘HavrixTM’ [SmithKline Beecham Biologicals]
- IPV inactivated polio virus
- types 1, 2 and 3 as is standard in the vaccine art, most preferably the Salk polio vaccine
- the immunogenic compositions of the invention are preferably formulated as a vaccine for in vivo administration to the host in such a way that the individual components of the composition are formulated such that the immunogenicity of individual components is not substantially impaired by other individual components of the composition.
- substantially impaired it is meant that upon immunisation, an antibody titre against each component is obtained which is more than 60%, preferably more than 70%, more preferably more than 80%, still more preferably more than 90%, and most preferably more than 95-100% of the titre obtained when the antigen is administered in isolation.
- the immunogenic compositions of the invention are preferably formulated as a vaccine for in vivo administration to the host, such that they confer an antibody titre superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects. This is an important test in the assessment of a vaccine's efficacy throughout the population. Antigens with an associated antibody titre above which a host is considered to be seroconverted against the antigen are well known, and such titres are published by organisations such as WHO. Preferably more than 80% of a statistically significant sample of subjects is seroconverted, more preferably more than 90%, still more preferably more than 93% and most preferably 96-100%.
- the immunogenic composition of the invention are preferably adjuvanted.
- Suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
- the adjuvant may also be selected to be a preferential inducer of a TH1 type of response to aid the cell mediated branch of the immune response.
- Th1-type cytokines tend to favour the induction of cell mediated immune responses to a given antigen, whilst high levels of Th2-type cytokines tend to favour the induction of humoral immune responses to the antigen.
- Suitable adjuvant systems which promote a predominantly Th1 response include, Monophosphoryl lipid A or a derivative thereof, particularly 3-de-O-acylated monophosphoryl lipid A, and a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt.
- An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative, particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
- a particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.
- the vaccine may additionally comprise a saponin, more preferably QS21.
- the formulation may also comprises an oil in water emulsion and tocopherol (WO 95/17210).
- Unmethylated CpG containing oligonucleotides (WO 96/02555) are also preferential inducers of a TH1 response and are suitable for use in the present invention.
- Aluminium salts are preferred adjuvants in the above immunogenic compositions.
- HepB should preferably be adsorbed onto aluminium phosphate before admixing with the other components.
- the polysaccharide conjugates may be unadjuvanted.
- the present invention also provides a method for producing a vaccine formulation comprising the step of mixing the components of the vaccine together with a pharmaceutically acceptable excipient.
- a particularly preferred DTPw composition of the invention comprises: TT, DT, Pw, HepB (preferably adsorbed onto aluminium phosphate), Hib (preferably conjugated onto TT and/or unadsorbed), MenA (preferably conjugated onto protein D), and MenC (preferably conjugated onto protein D).
- the vaccine may be supplied in 2 containers, the first containing DTPw-HepB in a liquid form, and a second containing Hib-MenA-MenC in a lyophilised form. The contents of the containers may be mixed extemporaneously before administering to a host in a single injection.
- an immunogenic composition or vaccine as herein described for use in a medicament.
- a method of immunising a human host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae , Hepatitis B virus, Haemophilus influenzae and N. meningitidis which method comprises administering to the host an immunoprotective dose of the immunogenic composition of the invention is also provided.
- the vaccine preparations of the present invention may be used to protect or treat a mammal susceptible to infection, by means of administering said vaccine via systemic or mucosal route.
- These administrations may include injection via the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or via mucosal administration to the oral/alimentary, respiratory, genitourinary tracts.
- each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 0.1-100 ⁇ g of polysaccharide, preferably 0.1-50 ⁇ g, preferably 0.1-10 ⁇ g, of which 1 to 5 ⁇ g is the most preferable range.
- the content of protein antigens in the vaccine will typically be in the range 1-100 ⁇ g, preferably 5-50 ⁇ g, most typically in the range 5 -25 ⁇ g.
- subjects may receive one or several booster immunisations adequately spaced.
- Vaccine preparation is generally described in Vaccine Design (“The subunit and adjuvant approach” (eds Powell M. F. & Newman M. J.) (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
- the inventors have also found that for vaccines comprising TT, DT, Pw and Hib, surprisingly a substantially lower dose of Hib can be used in the combination vaccine (compared with the standard dose of 10 ⁇ g per 0.5 mL dose) to obtain at least equivalent antibody titres against the H. influenzae type b capsular polysaccharide antigen. This is contrary to what would have been expected.
- a multi-valent immunogenic composition comprising killed whole-cell Bordetella pertussis (Pw), tetanus toxoid (TT), diphtheria toxoid (DT), and a conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B (Hib—preferably conjugated to TT, DT or CRM197), wherein the amount of conjugate per 0.5 mL dose of bulk vaccine is 1-8 ⁇ g, and the immunogenicity of the conjugate is equivalent or improved over such compositions comprising larger amounts of conjugate.
- Hepatitis B surface antigen may also be included.
- the amount of conjugate per 0.5 mL dose of bulk vaccine is less than 10 ⁇ g (of polysaccharide in the conjugate), more preferably 1-7 or 2-6 ⁇ g, and most preferably about 2.5, 3, 4 or 5 ⁇ g.
- the Hib conjugate is not adsorbed onto aluminium adjuvant salt before being mixed with the DTPw vaccine.
- combination vaccines comprising a Hib conjugate elicits significantly higher anti-Hib antibody titres in a host (compared with a monovalent, unadsorbed Hib conjugate vaccine) if the Hib conjugate is administered in a vaccine additionally comprising 1, but particularly 2 or more additional bacterial polysaccharides and the Hib polysaccharide (and preferably all the polysaccharides) of the vaccine are not adsorbed onto an adjuvant (particularly aluminium salts).
- a further, independent, aspect of the invention therefore is the provision of a multi-valent immunogenic composition
- a multi-valent immunogenic composition comprising a conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B (Hib), wherein said composition additionally comprises 1, but particularly 2 or more further bacterial polysaccharides (preferably more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) capable of conferring protection to a host against infection by the bacteria from which they are derived, and wherein the Hib polysaccharide (and preferably none of said polysaccharides) in the composition are adsorbed onto an aluminium adjuvant salt. Most preferably there is no aluminium adjuvant salt present in the composition.
- an antigen not being ‘adsorbed onto an aluminium adjuvant salt’ it is meant that an express or dedicated adsorption step for the antigen on fresh aluminium adjuvant salt is not involved in the process of formulating the composition.
- Hib may be conjugated to any carrier which can provide at least one T-helper epitope (examples of which are described above), and preferably tetanus toxoid.
- the further bacterial polysaccharides are also conjugated to a carrier protein (examples of which are described above).
- the capsular polysaccharide of H. influenzae type B and the further polysaccharides are not conjugated to the same carrier (Hib and none of the further polysaccharides share the same carrier), particularly where the carrier is CRM197.
- at least one of the polysaccharides of the composition is conjugated onto protein D, however this is not essential for the performance of the invention—indeed neither the Hib nor any of the further polysaccharides need be conjugated onto protein D.
- Hib and further bacterial polysaccharides (and conjugates thereof) are the only antigens present in the composition.
- the further bacterial polysaccharides are selected from a group consisting of: N. meningitidis serogroup A capsular polysaccharide (MenA), N. meningitidis serogroup C capsular polysaccharide (MenC), N. meningitidis serogroup Y capsular polysaccharide (MenY), N.
- meningitidis serogroup W capsular polysaccharide MenW
- Group B Streptococcus group I capsular polysaccharide Group B Streptococcus group II capsular polysaccharide
- Group B Streptococcus group III capsular polysaccharide Group B Streptococcus group IV capsular polysaccharide
- Group B Streptococcus group V capsular polysaccharide Staphylococcus aureus type 5 capsular polysaccharide
- Staphylococcus aureus type 8 capsular polysaccharide Vi polysaccharide from Salmonella typhi, N. meningitidis LPS, M. catarrhalis LPS, and H.
- LPS lipo-polysaccharide
- lipo-oligosaccharide lipo-polysaccharide where the lipid A portion has been detoxified by any of a number of known methods (see for example WO 97/18837 or WO 98/33923), or any molecule comprising the O-polysaccharide derived from said LPS.
- N. meningitidis LPS it is meant one or more of the 12 known immunotypes (L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 or L12).
- the amount of PS in each of the above conjugates may be 5 or 10 ⁇ g each per 0.5 mL human dose.
- the above compositions may also include N. meningitidis serotype B outer membrane vesicles, or one or more N. meningitidis serotype B outer membrane (surface-exposed) proteins, or one or more N. meningitidis LPS (as defined above) to make a global meningitis vaccine.
- MenA, MenC and MenY are either TT or PD conjugates.
- the further bacterial polysaccharides may also be selected from any of the capsular pneumococcal polysaccharides (preferably more than 7, more preferably 11 or more, and most preferably 13 or more) such as from serotype: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F or 33F.
- the pneumococcal polysaccharides are conjugated (most preferably PD conjugates).
- pneumococcal polysaccharides derived from at least four serotypes may be selected from the above list. More preferably polysaccharides from more than 7 serotypes are included in the composition, for instance at least 11 serotypes.
- the composition in one embodiment includes 11 capsular polysaccharides derived from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (preferably conjugated).
- polysaccharide antigens preferably conjugated
- further polysaccharide antigens for example 23 valent (such as serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), are also contemplated by the invention.
- serotypes 8 and 12F are advantageously included to form a 13/15 valent vaccine.
- serotypes 6A and 19A are advantageously included to form a 13 valent vaccine.
- the pneumococcal polysaccharides may or may not be adsorbed onto aluminium adjuvant salts.
- GMC post-primary geometric mean concentrations
- Another indication that no detrimental effect has occurred is if the % of subjects with antibody concentrations of no less than 0.5 ⁇ g/ml differs by no more than 10% (preferably less than 9, 7, 5, 3 or 1%) when comparing 1 month post-primary administrations of the vaccine of the invention versus the vaccine without Hib conjugate.
- Hib and further bacterial ‘polysaccharides’ the preferred embodiment
- the invention may be extended to Hib and further bacterial ‘oligosaccharides’ (which naturally have a low number of repeat units, or which are polysaccharides reduced in size for manageability, but are still capable of inducing a protective immune response in a host) which are well known in the vaccine art.
- the multi-valent immunogenic composition of this aspect of the invention is formulated as a vaccine for in vivo administration to the host wherein the individual components of the composition are formulated such that the immunogenicity of individual components is not impaired by other individual components of the composition (see above definition).
- the individual components of the composition are formulated such that the immunogenicity of individual components is not impaired by other individual components of the composition (see above definition).
- no (significantly) detrimental effect occurs to the further bacterial polysaccharides (in terms of protective efficacy) in the combination as compared to their administration in isolation.
- the multi-valent immunogenic composition of this aspect of the invention is formulated as a vaccine for in vivo administration to the host, which confers an antibody titre superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects (see above definition).
- compositions of this aspect of the invention are preferably formulated in a vaccine.
- the use of the of the multi-valent immunogenic composition of this aspect of the invention in the manufacture of a medicament for the treatment or prevention of diseases caused by infection by Haemophilus influenzae (and preferably also those organisms from which the further bacterial polysaccharides are derived) is also envisioned, as is a method of immunising a human host against disease caused by Haemophilus influenzae (and preferably also those organisms from which the further bacterial polysaccharides are derived), which method comprises administering to the host an immunoprotective dose of the multi-valent immunogenic composition of this aspect of the invention.
- a process for making the multi-valent immunogenic composition of this aspect of the invention comprising the step of mixing together the individual components. If the further bacterial polysaccharides are to be adsorbed onto an aluminium adjuvant salt, this should be done before Hib is added to the formulation. Preferably an excess of aluminium adjuvant salt should not be used. Most preferably the Hib should be added to the aluminium adjuvanted further polysaccharide extemporanoeusly to the composition being administered to a host.
- MenAC-Hib N. meningitidis type A capsular polysaccharide conjugated onto protein D (using the CDAP technique), N. meningitidis type C capsular polysaccharide conjugated onto protein D and H. influenzae type b capsular polysaccharide conjugated onto TT were mixed together in an amount of 5 ⁇ g of each polysaccharide in each conjugate per 0.5 mL human dose. The pH was adjusted to 6.1, and was lyophilised in the presence of sucrose.
- MenC-Hib N. meningitidis type C capsular polysaccharide conjugated onto protein D (using the CDAP technique) and H. influenzae type b capsular polysaccharide conjugated onto TT were mixed together in an amount of 5 ⁇ g of polysaccharide in each conjugate per 0.5 mL human dose. The pH was adjusted to 6.1, and was lyophilised in the presence of sucrose.
- N. meningitidis type A capsular polysaccharide conjugated onto protein D (using the CDAP techniques), N. meningitidis type C capsular polysaccharide conjugated onto protein D and H. influenzae type b capsular polysaccharide conjugated onto TT were each adsorbed separately in saline onto aluminium phosphate (5 ⁇ g of each conjugate onto 100 ⁇ g, 100 ⁇ g and 60 ⁇ g Al 3+ , respectively, per dose).
- the adsorbed vaccines were mixed together at a pH of 6.1 and were lyophilised in the presence of sucrose.
- Study MenAC-Hib 001 evaluates the immunogenicity, reactogenicity and safety induced by MenC-Hib and MenAC-Hib (adsorbed and unadsorbed) made by the above example given as a three-dose primary vaccination in infants.
- the study was a phase II, randomized study and included five study groups.
- the formulations that were evaluated were a lyophilized plain and adsorbed formulation of Men AC-Hib and a plain formulation of MenC-Hib. These three formulations were administered to the three first study groups of infants at 3, 4 and 5 months of age; Tritanrix-HepBTM was given concomitantly (as a separate injection) to these three groups.
- Men AC-Hib The plain formulation of Men AC-Hib was also reconstituted within a liquid diphtheria, tetanus, whole-cell pertussis, hepatitis B combined vaccine (Tritanrix-HepBTM) and administered as a single injection to the fourth study group of infants at 3, 4 and 5 months of age.
- the fifth group (control) was administered Tritanrix-HepTM-Hib vaccine at 3, 4, 5 months of age.
- the study was open, but the two first groups receiving the two different formulations of MenAC-Hib were double-blind, as well as the two last groups receiving the Tritanrix-HepBTM-MenAC-Hib and the Tritanrix-HepBTM-Hib vaccines.
- each formulation that was evaluated induced a good immune response against each antigen (antibodies against meningococcal groups A and C, Poly-Ribosyl-Phosphate (the capsular polysaccharide of H. influenzae type b), Diphtheria toxoid, Tetanus toxoid, Bordetella pertussis and hepatitis B were measured).
- antigen antigen against meningococcal groups A and C
- Poly-Ribosyl-Phosphate the capsular polysaccharide of H. influenzae type b
- Diphtheria toxoid the capsular polysaccharide of H. influenzae type b
- Tetanus toxoid the capsular polysaccharide of H. influenzae type b
- Bordetella pertussis Bordetella pertussis and hepatitis B were measured.
- Each vaccine formulation was well tolerated.
- This test is an ELISA test that measures IgG content against meningococcal polysaccharide A.
- FIG. 3 shows the RCC graphs of the data. There is no interference of the MenA polysaccharide antigen to induce at least the same quantity of antibodies when present in a DTPw-HepB/MenAC-Hib vaccine.
- This test is a bactericidal test that measures the bactericidal antibodies against meningococcus serogroup A. There is no interference of the MenA polysaccharide antigen to induce at least the same quantity of antibodies when present in a DTPw-HepB/MenAC-Hib vaccine.
- This test is an ELISA test that measures IgG content against meningococcal polysaccharide C.
- FIG. 4 shows a RCC graph of the data.
- SBA-MenC is a bactericidal test that measures the bactericidal activity of the serum against meningococcus C. It is a measure of functional antibodies.
- FIG. 5 shows a RCC graph of the data. There is no interference on the MenC polysaccharide antigen to induce the same quantity of functional antibodies when it is present in a DTPw-HepB/MenAC-Hib vaccine.
- This test is a bactericidal test that measures the bactericidal antibodies against meningococcus serogroup A. It is a measure of functional antibodies. There is no interference on the MenC polysaccharide antigen to induce the same quantity of functional antibodies when it is present in a DTPw-HepB/MenAC-Hib vaccine. Seroconversion rates of antibodies to diphtheria, tetanus, B.
- GMT Geometric Mean Titre
- D T BP HepB MenAC-Hib 2.02 2.18 74.9 357.5 [1.62-2.51] [1.69-2.82] [61.9-90.8] [236.2- 541.2] DTPw-HepB/ 1.69 2.42 71.6 380.2 MenAC-Hib [1.36-2.09] [1.96-3.00] [59.7-85.9] [265.1- 545.2] DTPw-HepB/ 1.26 2.08 69.0 379.1 Hiberix [1.03-1.53] [1.67-2.59] [58.2-81.8] [265.0- 542.2]
- the pneumococcal vaccine had previously been adsorbed onto 0.5 mg Al 3+ (as AlPO 4 ).
- Example 4 The vaccine of Example 4 and a control vaccine were administered in a three-dose (3, 4, 5 months of age) schedule to German infants.
- the immune response results were as follows.
- Anti pneumococcal IgG antibodies GMC ( ⁇ g/ml) (By Elisa) PS Anti- Group A Group D body Timing N S + [%] GMC N S + [%] GMC Anti-1 PIII 30 100 1.23 33 100 0.99 Anti-3 PIII 30 100 2.04 33 97.0 1.20 Anti-4 PIII 30 100 0.98 33 100 1.03 Anti-5 PIII 30 100 1.33 33 100 1.34 Anti-6B PIII 30 100 0.54 33 100 0.62 Anti-7F PIII 30 100 1.60 33 100 1.33 Anti-9V PIII 30 100 1.61 33 100 1.21 Anti-14 PIII 30 100 2.27 33 100 2.32 Anti-18C PIII 30 100 1.06 33 100 1.04 Anti-19F PIII 30 100 2.05 33 100 1.92 Anti-23F PIII 30 96.7 0.75 33 100 0.76
- Hiberix (unadsorbed Hib-TT conjugate) has a GMC after a similar administration schedule of about 6 ⁇ g/ml.
- Group 1 DTPw-HepB extemporaneously mixed with a full dose of Hib-TT (PRP 10 ⁇ g; TT 10-20 ⁇ g; lactose 12.6 ⁇ g; aluminium [as salts] 0.15 mg);
- Group 2 DTPw-HepB extemporaneously mixed with a half dose of Hib-TT (PRP 5 ⁇ g; TT 10-20 ⁇ g; lactose 10 ⁇ g; aluminium [as salts] 0.0755 mg);
- Group 3 DTPw-HepB extemporaneously mixed with a quarter dose of Hib-TT (PRP 2.5 ⁇ g; TT 5-10 ⁇ g; lactose 10 ⁇ g; aluminium [as salts] 0.036 mg);
- Group 4 DTPw-HepB concomitantly administered (in different limbs) with a fill dose of Hib-TT.
- GTTs Geometric Mean Titers
- the low dose formulation surprisingly has the highest GMT values. This effect should be even greater if the Hib-TT vaccine is unadsorbed.
Abstract
A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminium adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide of H. influenzae b, and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.
Description
- The present invention relates to new combination vaccine formulations. Combination vaccines (which provide protection against multiple pathogens) are very desirable in order to minimise the number of immunisations required to confer protection against multiple pathogens, to lower administration costs, and to increase acceptance and coverage rates. The well-documented phenomenon of antigenic competition (or interference) complicates the development of multi-component vaccines. Antigenic interference refers to the observation that administering multiple antigens often results in a diminished response to certain antigens relative to the immune response observed when such antigens are administered individually.
- Combination vaccines are known which can preventBordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, and optionally Hepatitis B virus and/or Haemophilus influenzae type b (see, for instance, WO 93/24148 and WO 97/00697).
- The present invention concerns the manufacture of the most ambitious multi-valent vaccines to date, the administration of which can prevent or treat infection byBordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis, and preferably also Hepatitis A virus and/or Polio virus, wherein the components of the vaccine do not significantly interfere with the immunological performance of any one component of the vaccine.
- Accordingly, in one aspect the present invention provides a multi-valent immunogenic composition for conferring protection in a host against disease caused byBordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis comprising:
- (a) either killed whole-cellBordetella pertussis (Pw), or two or more acellular pertussis components (Pa) [preferably the former],
- (b) tetanus toxoid (TT),
- (c) diphtheria toxoid (DT),
- (d) Hepatitis B surface antigen (HepB),
- (e) a conjugate of a carrier protein and the capsular polysaccharide ofH. influenzae type B (Hib), and
- (f) one or more conjugates of a carrier protein and a capsular polysaccharide of a bacterium selected from the groupN. meningitidis type A (MenA) and N. meningitidis type C (MenC).
- Methods of preparing tetanus toxoid (TT) are well known in the art. For instance, TT is preferably produced by purification of the toxin from a culture ofClostridium tetani followed by chemical detoxification, but is alternatively made by purification of a recombinant, or genetically detoxified analogue of the toxin (for example, as described in EP 209281). ‘Tetanus toxoid’ also encompasses immunogenic fragments of the fill-length protein (for instance Fragment C—see EP 478602).
- Methods of preparing diphtheria toxoid (DT) are also well known in the art. For instance, DT is preferably produced by purification of the toxin from a culture ofCorynebacterium diphtheriae followed by chemical detoxification, but is alternatively made by purification of a recombinant, or genetically detoxified analogue of the toxin (for example, CRM197, or other mutants as described in U.S. Pat. Nos. 4,709,017, 5,843,711, 5,601,827, and 5,917,017).
- Acellular pertussis components (Pa) are well known in the art. Examples include pertussis toxoid (PT), filamentous haemagluttinin (FHA), pertactin (PRN) and
agglutinogens - Methods of preparing killed, whole-cellBordetella pertussis (Pw) suitable for this invention is disclosed in WO 93/24148, as are suitable formulation methods for producing DT-TT-Pw-HepB and DT-TT-Pa-HepB vaccines.
- The bacterial capsular polysaccharide conjugates may comprise any carrier peptide, polypeptide or protein comprising at least one T-helper epitope. Preferably the carrier protein(s) used is selected from the group comprising: tetanus toxoid, diphtheria toxoid, CRM197, recombinant diphtheria toxin (as described in any of U.S. Pat. No. 4,709,017, WO 93/25210, WO 95/33481, or WO 00/48638), pneumolysin (preferably chemically detoxified, or a detoxified mutant) fromS. pneumoniae, OMPC from N. meningitidis, and protein D (PD) from H. influenzae (EP 594610). Due to the known effect of carrier suppression, it is advantageous if in each of the compositions of the invention the polysaccharide antigens contained therein (‘n’ antigens) are conjugated to more than one carrier. Thus (n−1) of the polysaccharides could be carried (separately) on one type of carrier, and 1 on a different carrier, or (n−2) on one, and 2 on two different carriers, etc. For example, in a vaccine containing 4 bacterial polysaccharide conjugates, 1, 2 or all four could be conjugated to different carriers). Protein D, however, is advantageously used as a carrier in the compositions of the invention as it may be used for various (2, 3, 4 or more) polysaccharides in a composition without a marked carrier suppression effect. Most preferably Hib is present as a TT conjugate, and MenA, MenC, MenY and MenW are either TT or PD conjugates. Protein D is also a useful carrier as it provides a further antigen which can provide protection against H influenzae.
- The polysaccharide may be linked to the carrier protein by any known method (for example, by Likhite, U.S. Pat. No. 4,372,945 and by Armor et al., U.S. Pat. No. 4,474,757). Preferably, CDAP conjugation is carried out (WO 95/08348).
- In CDAP, the cyanylating reagent 1-cyano-dimethylaminopyridinium tetrafluoroborate (CDAP) is preferably used for the synthesis of polysaccharide-protein conjugates. The cyanilation reaction can be performed under relatively mild conditions, which avoids hydrolysis of the alkaline sensitive polysaceharides. This synthesis allows direct coupling to a carrier protein.
- The above immunogenic composition may further comprise one, two, three, four, five, six or seven components selected from the following list:N. meningitidis type Y polysaccharide [MenY] (preferably conjugated), N. meningitidis type W polysaccharide [MenW] (preferably conjugated), the Vi polysaccharide of Salmonella typhi, N. meningitidis (preferably serotype B) outer membrane vesicles, one or more N. meningitidis (preferably serotype B) outer membrane (surface-exposed) proteins, killed, attenuated Hepatitis A virus (HepA—preferably the product known as ‘Havrix™’ [SmithKline Beecham Biologicals]), and inactivated polio virus (IPV—preferably comprising
types - The immunogenic compositions of the invention are preferably formulated as a vaccine for in vivo administration to the host in such a way that the individual components of the composition are formulated such that the immunogenicity of individual components is not substantially impaired by other individual components of the composition. By not substantially impaired, it is meant that upon immunisation, an antibody titre against each component is obtained which is more than 60%, preferably more than 70%, more preferably more than 80%, still more preferably more than 90%, and most preferably more than 95-100% of the titre obtained when the antigen is administered in isolation.
- The immunogenic compositions of the invention are preferably formulated as a vaccine for in vivo administration to the host, such that they confer an antibody titre superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects. This is an important test in the assessment of a vaccine's efficacy throughout the population. Antigens with an associated antibody titre above which a host is considered to be seroconverted against the antigen are well known, and such titres are published by organisations such as WHO. Preferably more than 80% of a statistically significant sample of subjects is seroconverted, more preferably more than 90%, still more preferably more than 93% and most preferably 96-100%.
- The immunogenic composition of the invention are preferably adjuvanted. Suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
- The adjuvant may also be selected to be a preferential inducer of a TH1 type of response to aid the cell mediated branch of the immune response.
- High levels of Th1-type cytokines tend to favour the induction of cell mediated immune responses to a given antigen, whilst high levels of Th2-type cytokines tend to favour the induction of humoral immune responses to the antigen.
- Suitable adjuvant systems which promote a predominantly Th1 response include, Monophosphoryl lipid A or a derivative thereof, particularly 3-de-O-acylated monophosphoryl lipid A, and a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt. An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative, particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210. The vaccine may additionally comprise a saponin, more preferably QS21. The formulation may also comprises an oil in water emulsion and tocopherol (WO 95/17210). Unmethylated CpG containing oligonucleotides (WO 96/02555) are also preferential inducers of a TH1 response and are suitable for use in the present invention.
- Aluminium salts are preferred adjuvants in the above immunogenic compositions. In particular, HepB should preferably be adsorbed onto aluminium phosphate before admixing with the other components. In order to minimise the levels of adjuvant (particularly aluminium salts) in the compositions of the invention, the polysaccharide conjugates may be unadjuvanted.
- The present invention also provides a method for producing a vaccine formulation comprising the step of mixing the components of the vaccine together with a pharmaceutically acceptable excipient.
- A particularly preferred DTPw composition of the invention comprises: TT, DT, Pw, HepB (preferably adsorbed onto aluminium phosphate), Hib (preferably conjugated onto TT and/or unadsorbed), MenA (preferably conjugated onto protein D), and MenC (preferably conjugated onto protein D). Preferably the vaccine may be supplied in 2 containers, the first containing DTPw-HepB in a liquid form, and a second containing Hib-MenA-MenC in a lyophilised form. The contents of the containers may be mixed extemporaneously before administering to a host in a single injection.
- In a further aspect of the present invention there is provided an immunogenic composition or vaccine as herein described for use in a medicament.
- In a still further aspect of the invention there is provided a use of the immunogenic compositions of the invention in the manufacture of a medicament for the treatment or prevention of diseases caused by infection byBordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis.
- Additionally, a method of immunising a human host against disease caused byBordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis, which method comprises administering to the host an immunoprotective dose of the immunogenic composition of the invention is also provided.
- The vaccine preparations of the present invention may be used to protect or treat a mammal susceptible to infection, by means of administering said vaccine via systemic or mucosal route. These administrations may include injection via the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or via mucosal administration to the oral/alimentary, respiratory, genitourinary tracts.
- The amount of antigen in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 0.1-100 μg of polysaccharide, preferably 0.1-50 μg, preferably 0.1-10 μg, of which 1 to 5 μg is the most preferable range.
- The content of protein antigens in the vaccine will typically be in the range 1-100 μg, preferably 5-50 μg, most typically in the range 5 -25 μg.
- Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
- Vaccine preparation is generally described in Vaccine Design (“The subunit and adjuvant approach” (eds Powell M. F. & Newman M. J.) (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
- Interestingly, the inventors have also found that for vaccines comprising TT, DT, Pw and Hib, surprisingly a substantially lower dose of Hib can be used in the combination vaccine (compared with the standard dose of 10 μg per 0.5 mL dose) to obtain at least equivalent antibody titres against theH. influenzae type b capsular polysaccharide antigen. This is contrary to what would have been expected.
- Accordingly, in a further embodiment of the invention there is provided a multi-valent immunogenic composition comprising killed whole-cellBordetella pertussis (Pw), tetanus toxoid (TT), diphtheria toxoid (DT), and a conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B (Hib—preferably conjugated to TT, DT or CRM197), wherein the amount of conjugate per 0.5 mL dose of bulk vaccine is 1-8 μg, and the immunogenicity of the conjugate is equivalent or improved over such compositions comprising larger amounts of conjugate. Optionally, Hepatitis B surface antigen may also be included.
- Preferably the amount of conjugate per 0.5 mL dose of bulk vaccine is less than 10 μg (of polysaccharide in the conjugate), more preferably 1-7 or 2-6 μg, and most preferably about 2.5, 3, 4 or 5 μg. Most preferably the Hib conjugate is not adsorbed onto aluminium adjuvant salt before being mixed with the DTPw vaccine.
- A further observation that the inventors have made is the fact that combination vaccines comprising a Hib conjugate elicits significantly higher anti-Hib antibody titres in a host (compared with a monovalent, unadsorbed Hib conjugate vaccine) if the Hib conjugate is administered in a vaccine additionally comprising 1, but particularly 2 or more additional bacterial polysaccharides and the Hib polysaccharide (and preferably all the polysaccharides) of the vaccine are not adsorbed onto an adjuvant (particularly aluminium salts).
- A further, independent, aspect of the invention therefore is the provision of a multi-valent immunogenic composition comprising a conjugate of a carrier protein and the capsular polysaccharide ofH. influenzae type B (Hib), wherein said composition additionally comprises 1, but particularly 2 or more further bacterial polysaccharides (preferably more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) capable of conferring protection to a host against infection by the bacteria from which they are derived, and wherein the Hib polysaccharide (and preferably none of said polysaccharides) in the composition are adsorbed onto an aluminium adjuvant salt. Most preferably there is no aluminium adjuvant salt present in the composition.
- By an antigen not being ‘adsorbed onto an aluminium adjuvant salt’ it is meant that an express or dedicated adsorption step for the antigen on fresh aluminium adjuvant salt is not involved in the process of formulating the composition.
- Hib may be conjugated to any carrier which can provide at least one T-helper epitope (examples of which are described above), and preferably tetanus toxoid.
- Preferably, the further bacterial polysaccharides are also conjugated to a carrier protein (examples of which are described above). In specific embodiments the capsular polysaccharide ofH. influenzae type B and the further polysaccharides are not conjugated to the same carrier (Hib and none of the further polysaccharides share the same carrier), particularly where the carrier is CRM197. In the preferred embodiments of the examples at least one of the polysaccharides of the composition is conjugated onto protein D, however this is not essential for the performance of the invention—indeed neither the Hib nor any of the further polysaccharides need be conjugated onto protein D.
- In a specific embodiment of the above invention, only Hib and further bacterial polysaccharides (and conjugates thereof) are the only antigens present in the composition.
- An amount of polysaccharide which capable of conferring protection to a host (an effective amount) can be readily determined by the skilled person. Generally, it is expected that each dose will comprise 0.1-100 μg of polysaccharide, preferably 0.1-50 μg, preferably 0.1-10 μg, of which 1 to 5 μg is the most preferable range. The Hib conjugate is preferably present in an amount of 3-15 μg (of polysaccharide in the conjugate), more preferably 4-12 μg and most preferably. 5-10 μg. In a preferred embodiment a total of no less than 2 μg of further polysaccharide (particularly when conjugated) is present in the composition per 0.5 mL dose, and preferably no less than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 25, 30, 35, 40, 45 or 50 μg are included. Preferably no more than 100 μg of further polysaccharide are included per 0.5 mL dose.
- Preferably the further bacterial polysaccharides are selected from a group consisting of:N. meningitidis serogroup A capsular polysaccharide (MenA), N. meningitidis serogroup C capsular polysaccharide (MenC), N. meningitidis serogroup Y capsular polysaccharide (MenY), N. meningitidis serogroup W capsular polysaccharide (MenW), Group B Streptococcus group I capsular polysaccharide, Group B Streptococcus group II capsular polysaccharide, Group B Streptococcus group III capsular polysaccharide, Group B Streptococcus group IV capsular polysaccharide, Group B Streptococcus group V capsular polysaccharide,
Staphylococcus aureus type 5 capsular polysaccharide, Staphylococcus aureus type 8 capsular polysaccharide, Vi polysaccharide from Salmonella typhi, N. meningitidis LPS, M. catarrhalis LPS, and H. influenzae LPS. By LPS it is meant either native lipo-polysaccharide (or lipo-oligosaccharide), or lipo-polysaccharide where the lipid A portion has been detoxified by any of a number of known methods (see for example WO 97/18837 or WO 98/33923), or any molecule comprising the O-polysaccharide derived from said LPS. By N. meningitidis LPS it is meant one or more of the 12 known immunotypes (L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 or L12). - Particularly preferred combinations are compositions containing or comprising: 1) conjugated Hib, conjugated MenA and conjugated MenC; 2) conjugated Hib, conjugated MenY and conjugated MenC; and 3) conjugated Hib and conjugated MenC. The amount of PS in each of the above conjugates may be 5 or 10 μg each per 0.5 mL human dose. Optionally, the above compositions may also includeN. meningitidis serotype B outer membrane vesicles, or one or more N. meningitidis serotype B outer membrane (surface-exposed) proteins, or one or more N. meningitidis LPS (as defined above) to make a global meningitis vaccine. Preferably MenA, MenC and MenY are either TT or PD conjugates.
- The further bacterial polysaccharides may also be selected from any of the capsular pneumococcal polysaccharides (preferably more than 7, more preferably 11 or more, and most preferably 13 or more) such as from serotype: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F or 33F. Preferably the pneumococcal polysaccharides are conjugated (most preferably PD conjugates).
- For instance pneumococcal polysaccharides derived from at least four serotypes (including 6B, 14, 19F and 23F for example), or from at least 7 serotypes (including 4, 6B, 9V, 14, 18C, 19F, and 23F for example) may be selected from the above list. More preferably polysaccharides from more than 7 serotypes are included in the composition, for instance at least 11 serotypes. For example the composition in one embodiment includes 11 capsular polysaccharides derived from
serotypes serotypes - For elderly vaccination (for instance for the prevention of pneumonia) it is advantageous to include serotypes 8 and 12F (and most preferably 15 and 22 as well) to the preferred 11 valent antigenic composition described above to form a 13/15 valent vaccine, whereas for infants or toddlers (where otitis media is of more concern) serotypes 6A and 19A are advantageously included to form a 13 valent vaccine.
- The pneumococcal polysaccharides may or may not be adsorbed onto aluminium adjuvant salts.
- Hib (preferably lyophilised) and the pneumococcal polysaccharides (preferably in a liquid form) may be mixed extemporaneously before administering to a host in a single administration/injection. With such a formulation it is possible, upon immunisation, to obtain antibody titres against Hib capsular polysaccharide in excess of 100% of the titre obtained when the Hib conjugate is administered in isolation. In preferred embodiments, no (significantly) detrimental effect occurs to the pneumococcal polysaccharide conjugates (in terms of protective efficacy) in the combination as compared to their administration in isolation. This can be assessed in terms of measuring post-primary geometric mean concentrations (GMC) of
anti-polysaccharide antibody 1 month after the last primary dose (primary doses being the priming administrations—usually 3—in the first year of life). The GMC (in μg/ml) for a vaccine of the invention should be preferably over 55% (more preferably over 60, 70, 80, or 90%) of the GMC when the pneumococcal polysaccharides are administered without the Hib conjugate. Another indication that no detrimental effect has occurred is if the % of subjects with antibody concentrations of no less than 0.5 μg/ml differs by no more than 10% (preferably less than 9, 7, 5, 3 or 1%) when comparing 1 month post-primary administrations of the vaccine of the invention versus the vaccine without Hib conjugate. - Although the above refers to Hib and further bacterial ‘polysaccharides’ (the preferred embodiment) it is envisaged that the invention may be extended to Hib and further bacterial ‘oligosaccharides’ (which naturally have a low number of repeat units, or which are polysaccharides reduced in size for manageability, but are still capable of inducing a protective immune response in a host) which are well known in the vaccine art.
- Preferably, the multi-valent immunogenic composition of this aspect of the invention is formulated as a vaccine for in vivo administration to the host wherein the individual components of the composition are formulated such that the immunogenicity of individual components is not impaired by other individual components of the composition (see above definition). Thus, in preferred embodiments, no (significantly) detrimental effect occurs to the further bacterial polysaccharides (in terms of protective efficacy) in the combination as compared to their administration in isolation.
- Preferably, the multi-valent immunogenic composition of this aspect of the invention is formulated as a vaccine for in vivo administration to the host, which confers an antibody titre superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects (see above definition).
- The compositions of this aspect of the invention are preferably formulated in a vaccine. The use of the of the multi-valent immunogenic composition of this aspect of the invention in the manufacture of a medicament for the treatment or prevention of diseases caused by infection byHaemophilus influenzae (and preferably also those organisms from which the further bacterial polysaccharides are derived) is also envisioned, as is a method of immunising a human host against disease caused by Haemophilus influenzae (and preferably also those organisms from which the further bacterial polysaccharides are derived), which method comprises administering to the host an immunoprotective dose of the multi-valent immunogenic composition of this aspect of the invention.
- A process for making the multi-valent immunogenic composition of this aspect of the invention is also provided, comprising the step of mixing together the individual components. If the further bacterial polysaccharides are to be adsorbed onto an aluminium adjuvant salt, this should be done before Hib is added to the formulation. Preferably an excess of aluminium adjuvant salt should not be used. Most preferably the Hib should be added to the aluminium adjuvanted further polysaccharide extemporanoeusly to the composition being administered to a host.
- All cited references and publications are incorporated by reference herein.
- Examples are provided solely for the purposes of illustration and are not intended to limit the scope of the invention.
- Preparation of a DT-TT-Pw-HepB (DTPw-HepB) Vaccine
- This was done as described in WO 93/24148. The vaccine is commercially available under the name Tritanrix-HepB™ (SmithKline Beecham Biologicals).
- Preparation of MenA-MenC-Hib (MenAC-Hib) Vaccines
- i) Unadjuvanted MenC-Hib or MenA-MenC-Hib
- MenAC-Hib:N. meningitidis type A capsular polysaccharide conjugated onto protein D (using the CDAP technique), N. meningitidis type C capsular polysaccharide conjugated onto protein D and H. influenzae type b capsular polysaccharide conjugated onto TT were mixed together in an amount of 5 μg of each polysaccharide in each conjugate per 0.5 mL human dose. The pH was adjusted to 6.1, and was lyophilised in the presence of sucrose.
- MenC-Hib:N. meningitidis type C capsular polysaccharide conjugated onto protein D (using the CDAP technique) and H. influenzae type b capsular polysaccharide conjugated onto TT were mixed together in an amount of 5 μg of polysaccharide in each conjugate per 0.5 mL human dose. The pH was adjusted to 6.1, and was lyophilised in the presence of sucrose.
- ii) Adjuvanted MenA-MenC-Hib
-
- Clinical Trial
- Study MenAC-Hib 001 evaluates the immunogenicity, reactogenicity and safety induced by MenC-Hib and MenAC-Hib (adsorbed and unadsorbed) made by the above example given as a three-dose primary vaccination in infants.
- The study was a phase II, randomized study and included five study groups. The formulations that were evaluated were a lyophilized plain and adsorbed formulation of Men AC-Hib and a plain formulation of MenC-Hib. These three formulations were administered to the three first study groups of infants at 3, 4 and 5 months of age; Tritanrix-HepB™ was given concomitantly (as a separate injection) to these three groups. The plain formulation of Men AC-Hib was also reconstituted within a liquid diphtheria, tetanus, whole-cell pertussis, hepatitis B combined vaccine (Tritanrix-HepB™) and administered as a single injection to the fourth study group of infants at 3, 4 and 5 months of age. The fifth group (control) was administered Tritanrix-Hep™-Hib vaccine at 3, 4, 5 months of age. The study was open, but the two first groups receiving the two different formulations of MenAC-Hib were double-blind, as well as the two last groups receiving the Tritanrix-HepB™-MenAC-Hib and the Tritanrix-HepB™-Hib vaccines. In summary the study groups were:
Group A MenA5μgC5μg-Hib5μg + DTPw-HepB N = 80 Group B MenA5μgC5μg-Hib5μg adsorbed + DTPw-HepB N = 80 Group C MenC5μg-Bib5μg +DTPw-HepB N = 80 Group D DTPw-HepB/MenA5μgC5μg-Hib5μg N = 80 Group E DTPw-HepB/MenA5μgC5μg-Hiberix N = 80 - The results showed that each formulation that was evaluated induced a good immune response against each antigen (antibodies against meningococcal groups A and C, Poly-Ribosyl-Phosphate (the capsular polysaccharide ofH. influenzae type b), Diphtheria toxoid, Tetanus toxoid, Bordetella pertussis and hepatitis B were measured). Each vaccine formulation was well tolerated.
Post III anti Poly-Ribosyl-Phosphate (PRP) ≧0.15 mcg/ml ≧1.0 mcg/ml GMC % % (mcg/ml) Group [L.L.-U.L.] [LL.-U.L.] [L.L.-U.L.] MenAC-Hib 98.5 98.5 19.0 N = 67 [92.0-100.0] [92.0-100.0] [13.7-26.3] MenAC-Hib_ads 100.0 90.1 7.6 N = 71 [94.9-100.0] [80.7-95.9] [5.6-10.7] MenC-Hib 100.0 95.5 12.6 N = 66 [94.6-100.0] [87.3-99.1] [9.2-17.2] DTPw-HepB/MenAC- 98.5 94.0 8.7 Hib N = 67 [92.0-100.0] [85.4-98.3] [6.2-12.2] DTPw-HepB/Hiberix 98.6 92.8 7.5 N = 69 [92.2-100.0] [83.9-97.6] [5.5-11.3] - 0.15 and 1.0 mcg/ml are typical titre thresholds which are observed to estimate seroprotection. There is no Hib interference in the DTPw-HepB/MenAC-Hib vaccine. This can also be seen in FIG. 1 which shows the reverse cumulative curve (RCC) of the data. In addition, it is surprising that the non-adsorbed MenAC-Hib vaccine displayed significantly higher anti PRP titre compared with the adsorbed formulation.
Post III anti Protein D IgG ≧100 ELU/ml GMC % (ELU/ml) Group [L.L.-U.L.] [L.L.-U.L.] MenAC-Hib 96.9 842 N = 64 [89.2-99.6] [662-1072] MenAC-Hib_ads 100.0 1480 N = 66 [94.6-100.0] [1195-1831] MenC-Hib 95.2 550 N = 63 [86.7-99.0] [426-709] DTPw-HepB/MenAC- Hib 100 1815 N = 63 [94.3-100.0] [1411-2335] DTPw-HepB/Hiberix 14.1 62.1 N = 64 [6.6-25.0] [54-72] - See also FIG. 2 for the respective RCC anti-PD IgG curves. As can be seen, all formulations induced an immune response to the carrier protein (protein D).
Post III anti PSA (capsular polysaccharide of meningococcus A) IgG ≧0.3 mcg/ml GMC % (mcg/ml) Group [L.L.-U.L.] [L.L.-U.L.] MenAC-Hib 100.0 7.4 N = 52 [93.2-100.0] [6.0-9.1] MenAC-Hib_ads 100.0 9.8 N = 55 [93.5-100.0] [7.9-12.2] MenC-Hib 17.9 0.22 N = 39 [7.5-33.5] [0.16-0.29] DTPw-HepB/MenAC-Hib 98.4 15.1 N = 61 [91.2-100.0] [11.5-19.9] DTPw-HepB/Hiberix 3.5 0.16 N = 57 [0.4-12.1] [0.14-0.18] - This test is an ELISA test that measures IgG content against meningococcal polysaccharide A. FIG. 3 shows the RCC graphs of the data. There is no interference of the MenA polysaccharide antigen to induce at least the same quantity of antibodies when present in a DTPw-HepB/MenAC-Hib vaccine.
Post III anti SBA against meningococcus serogroup A ≧1:8 % GMT Group [L.L.-U.L.] [L.L.-U.L.] MenAC-Hib 92.5 40.1 N = 52 [79.6-98.4] [26.2-61.4] MenAC-Hib_ads 90.9 40.6 N = 44 [78.3-97.5] [24.5-67.0] MenC-Hib Not done Not done N = 0 DTPw-HepB/MenAC-Hib 92.5 67.7 N = 50 [79.6-98.4] [45.3-101.1] DTPw-HepB/Hiberix 0.0 0.16 N = 57 [0.0-8.0] [0.14-0.18] - This test is a bactericidal test that measures the bactericidal antibodies against meningococcus serogroup A. There is no interference of the MenA polysaccharide antigen to induce at least the same quantity of antibodies when present in a DTPw-HepB/MenAC-Hib vaccine.
Post III anti PSC (meningococcus C capsular polysaccharide) IgG and SBA-MenC Anti-PSC IgG SBA-MenC % ≧ 0.3 mcg/ml GMC % ≧ 1:8 GMT Group [L.L.-U.L.] [L.L.-U.L.] [L.L.-U.L.] [L.L.-U.L.] MenAC-Hib 100.0 6.9 96.1 322.5 N = 52/51 [93.2-100.0] [5.7-8.2] [86.5-99.5] [208.7-498.5] MenAC-Hib_ads 100.0 10.4 86.0 144.6 N = 55/57 [93.5-100.0] [8.6-12.7] [74.2-93.7] [87.1-239.8] MenC-Hib 100.0 6.4 97.3 270.8 N = 40/37 [91.2-100.0] [5.2-7.9] [85.8-99.9] [167.7-437.3] DTPw-HepB/MenAC-Hib 100.0 12.1 91.8 394.2 N = 61/61 [94.1-100.0] [10.2-14.4] [81.9-97.3] [244.8-634.9] DTPw-HepB/Hiberix 3.5 0.16 1.7 4.4 N = 57/59 [0.4-12.1] [0.14-0.18] [0.0-9.1] [3.6-5.3] - This test is an ELISA test that measures IgG content against meningococcal polysaccharide C. FIG. 4 shows a RCC graph of the data. SBA-MenC is a bactericidal test that measures the bactericidal activity of the serum against meningococcus C. It is a measure of functional antibodies. FIG. 5 shows a RCC graph of the data. There is no interference on the MenC polysaccharide antigen to induce the same quantity of functional antibodies when it is present in a DTPw-HepB/MenAC-Hib vaccine.
Post III SBA-MenC against meningococcus serogroup C SBA-MenC % ≧ 1:8 GMT Group [L.L.-U.L] [L.L.-U.L.] MenAC-Hib 95.1 293.4 N = 61 [86.3-99.0] [195.6-440.3] MenAC-Hib_ads 85.1 151.4 N = 67 [74.3-92.6] [94.2-242.4] MenC-Hib 96.4 297.8 N = 55 [87.5-99.6] [201.4-440.4] DTPw-HepB/MenAC-Hib 93.4 426.9 N = 61 [84.1-98.2] [271.2-671.9] DTPw-HepB/Hiberix 1.6 4.4 N = 62 [0.0-8.7] [3.7-5.2] - This test is a bactericidal test that measures the bactericidal antibodies against meningococcus serogroup A. It is a measure of functional antibodies. There is no interference on the MenC polysaccharide antigen to induce the same quantity of functional antibodies when it is present in a DTPw-HepB/MenAC-Hib vaccine.
Seroconversion rates of antibodies to diphtheria, tetanus, B. pertussis cells and HepB Schedule (3-4-5 months) D T BP HepB MenAC-Hib 98.5 98.5 95.5 92.5 [92.0-100] [92.0-100] [87.3-99.1] [83.4-97.5] DTPw-HepB/ 98.5 100 97.0 97.0 MenAC-Hib [92.0-100.0] [94.6-100] [89.5-99.6] [89.6-99.6] DTPw-HepB/ 100 100 97.1 97.1 Hiberix [94.8-100.0] [94.7-100] [89.8-99.6] [89.9-99.6] -
Geometric Mean Titre (GMT) of antibodies to diphtheria, tetanus, B. pertussis cells and HepB Schedule (3-4-5 months) D T BP HepB MenAC-Hib 2.02 2.18 74.9 357.5 [1.62-2.51] [1.69-2.82] [61.9-90.8] [236.2- 541.2] DTPw-HepB/ 1.69 2.42 71.6 380.2 MenAC-Hib [1.36-2.09] [1.96-3.00] [59.7-85.9] [265.1- 545.2] DTPw-HepB/ 1.26 2.08 69.0 379.1 Hiberix [1.03-1.53] [1.67-2.59] [58.2-81.8] [265.0- 542.2] - From the previous two tables it was observed that the immune response to DT, TT, Pw and HepB are similar to that obtained with the registered Tritanrix-HepB vaccine in terms of both seroconversion and GMT.
- Preparation of a Hib-11 valent pneumococcal conjugate (Hib/Strep11V) Vaccine
-
serotypes - Clinical Trials on the Vaccine of Example 4
- The vaccine of Example 4 and a control vaccine were administered in a three-dose (3, 4, 5 months of age) schedule to German infants.
- The immune response results (measured 1 month after the last primary administration) were as follows.
Anti pneumococcal IgG antibodies: GMC (μg/ml) (By Elisa) PS Anti- Group A Group D body Timing N S + [%] GMC N S + [%] GMC Anti-1 PIII 30 100 1.23 33 100 0.99 Anti-3 PIII 30 100 2.04 33 97.0 1.20 Anti-4 PIII 30 100 0.98 33 100 1.03 Anti-5 PIII 30 100 1.33 33 100 1.34 Anti-6B PIII 30 100 0.54 33 100 0.62 Anti-7F PIII 30 100 1.60 33 100 1.33 Anti-9V PIII 30 100 1.61 33 100 1.21 Anti-14 PIII 30 100 2.27 33 100 2.32 Anti-18C PIII 30 100 1.06 33 100 1.04 Anti-19F PIII 30 100 2.05 33 100 1.92 Anti-23F PIII 30 96.7 0.75 33 100 0.76 -
Percent of subjects with antibody concentrations no less than 0.5 μg/ ml group PS 1 3 4 5 6B 7F 7V 14 18C 19F 23F D 84.8 87.9 87.9 90.9 51.5 90.9 93.9 97.0 81.8 97.0 72.7 A 86.7 96.7 76.7 90.0 50.0 93.3 90.0 90.0 80.0 96.7 66.7 -
Anti PRP antibodies: GMC (μg/ml) (By Elisa) Group D (N = 34) ≧1 μg/ml GMC n [%] [μg/ml] Anti- PIII 33 100 10.75 PRP - Hiberix (unadsorbed Hib-TT conjugate) has a GMC after a similar administration schedule of about 6 μg/ml.
- The immune response, in terms of ELISA antibodies, of infants who received the 11Pn-PD/Hib vaccine was similar to that observed for those who received the 11Pn-PD vaccine for all of the serotypes, with the exception of
serotypes - The 11Pn-PD/Hib vaccine induced functional (opsonophagocytic) antibodies to all 11 serotypes.
- Combining the Hib vaccine with the pneumococcal conjugate vaccine did not significantly interfere with the pneumococcal immune response and surprisingly enhanced the anti PRP response compared to both the registered vaccines Infanrix-HeXa and Hiberix.
- Clinical Trial on the Effect of Lower Amounts of Hib in a DTPwHepB Vaccine
- A randomized trial to assess the immunogenicity of a Hib-TT conjugate vaccine at various doses in SB Biologicals DTPwHepB (Tritanrix™-HB) vaccine was carried out as a primary vaccination in healthy infants at 6, 10 and 14 weeks of age.
- 544 subjects in four groups (136 each) were administered with the following vaccines: Group 1: DTPw-HepB extemporaneously mixed with a full dose of Hib-TT (
PRP 10 μg; TT 10-20 μg; lactose 12.6 μg; aluminium [as salts] 0.15 mg); Group 2: DTPw-HepB extemporaneously mixed with a half dose of Hib-TT (PRP 5 μg; TT 10-20 μg;lactose 10 μg; aluminium [as salts] 0.0755 mg); Group 3: DTPw-HepB extemporaneously mixed with a quarter dose of Hib-TT (PRP 2.5 μg; TT 5-10 μg;lactose 10 μg; aluminium [as salts] 0.036 mg); Group 4: DTPw-HepB concomitantly administered (in different limbs) with a fill dose of Hib-TT. - Geometric Mean Titers (GMTs) of anti-PRP antibodies one month after the third dose were as follows:
Group N GMT 95% Conf. Interval 1 130 14.766 11.835 18.423 2 124 17.304 14.209 21.074 3 124 21.010 16.950 26.044 4 126 22.954 18.463 28.538 - The low dose formulation surprisingly has the highest GMT values. This effect should be even greater if the Hib-TT vaccine is unadsorbed.
Claims (29)
1. A multi-valent immunogenic composition comprising a conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B, wherein said composition additionally comprises 2 or more further bacterial polysaccharides capable of conferring protection to a host against infection by the bacteria from which they are derived, and wherein the H. influenzae type B capsular polysaccharide conjugate is not adsorbed onto an aluminium adjuvant salt.
2. The multi-valent immunogenic composition of claim 1 , which comprises more than 7 further bacterial polysaccharides.
3. The multi-valent immunogenic composition of claim 2 , wherein the further bacterial polysaccharides are pneumococcal capsular polysaccharides.
4. The multi-valent immunogenic composition of claims 1-3, wherein none of the polysaccharides in the composition are adsorbed onto an aluminium adjuvant salt.
5. The multi-valent immunogenic composition of claims 1-4, wherein the further bacterial polysaccharides are selected from a group consisting of: N. meningitidis serogroup A capsular polysaccharide, N. meningitidis serogroup C capsular polysaccharide, N. meningitidis serogroup Y capsular polysaccharide, N. meningitidis serogroup W capsular polysaccharide, Streptococcus pneumoniae serotype 1 capsular polysaccharide, S. pneumoniae serotype 2 capsular polysaccharide, S. pneumoniae serotype 3 capsular polysaccharide, S. pneumoniae serotype 4 capsular polysaccharide, S. pneumoniae serotype 5 capsular polysaccharide, S. pneumoniae serotype 6A capsular polysaccharide, S. pneumoniae serotype 6B capsular polysaccharide, S. pneumoniae serotype 7F capsular polysaccharide, S. pneumoniae serotype 8 capsular polysaccharide, S. pneumoniae serotype 9N capsular polysaccharide, S. pneumoniae serotype 9V capsular polysaccharide, S. pneumoniae serotype 10A capsular polysaccharide, S. pneumoniae serotype 11A capsular polysaccharide, S. pneumoniae serotype 12F capsular polysaccharide, S. pneumoniae serotype 14 capsular polysaccharide, S. pneumoniae serotype 15B capsular polysaccharide, S. pneumoniae serotype 17F capsular polysaccharide, S. pneumoniae serotype 18C capsular polysaccharide, S. pneumoniae serotype 19A capsular polysaccharide, S. pneumoniae serotype 19F capsular polysaccharide, S. pneumoniae serotype 20 capsular polysaccharide, S. pneumoniae serotype 22F capsular polysaccharide, S. pneumoniae serotype 23F capsular polysaccharide, S. pneumoniae serotype 33F capsular polysaccharide, Group B Streptococcus group I capsular polysaccharide, Group B Streptococcus group II capsular polysaccharide, Group B Streptococcus group III capsular polysaccharide, Group B Streptococcus group IV capsular polysaccharide, Group B Streptococcus group V capsular polysaccharide, Staphylococcus aureus type 5 capsular polysaccharide, Staphylococcus aureus type 8 capsular polysaccharide, Vi polysaccharide from Salmonella typhi, N. meningitides LPS, M. catarrhalis LPS, and H. influenzae LPS.
6. The multi-valent immunogenic composition of claims 1-5, wherein the further bacterial polysaccharides are conjugated to a carrier protein.
7. The multi-valent immunogenic composition of claims 1-6, wherein the carrier protein(s) used is selected from the group comprising: tetanus toxoid, diphtheria toxoid, CRM197, recombinant diphtheria toxin, OMPC from N. meningitidis, pneumolysin from S. pneumoniae and protein D from H. influenzae.
8. The multi-valent immunogenic composition of claim 6 or 7, wherein the capsular polysaccharide of H. influenzae type B and the further polysaccharides are not conjugated to the same carrier.
9. The multi-valent immunogenic composition of claim 8 , wherein the capsular polysaccharide of H. influenzae type B and the further polysaccharides are not all conjugated to CRM197.
10. The use of the multi-valent immunogenic composition of claims 1-9 in the manufacture of a medicament for the treatment or prevention of diseases caused by infection by Haemophilus influenzae.
11. A method of immunising a human host against disease caused by Haemophilus influenzae, which method comprises administering to the host an immunoprotective dose of the multi-valent immunogenic composition of claims 1-9.
12. A multi-valent immunogenic composition for conferring protection in a host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis comprising:
a) either killed whole-cell Bordetella pertussis, or two or more acellular pertussis components,
b) tetanus toxoid,
c) diphtheria toxoid,
d) Hepatitis B surface antigen,
e) a conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B, and
f) one or more conjugates of a carrier protein and a capsular polysaccharide of a bacterium selected from the group N. meningitidis type A and N. meningitidis type C.
13. The immunogenic composition of claim 12 further comprising one or more conjugates of a carrier protein and a capsular polysaccharide of a bacterium selected from the group N. meningitidis type Y and N. meningitidis type W.
14. The immunogenic composition of claim 12 or 13 further comprising killed, attenuated Hepatitis A virus.
15. The immunogenic composition of claims 12-14 further comprising inactivated polio virus.
16. The immunogenic composition of claims 12-15 wherein the carrier protein(s) used is selected from the group comprising: tetanus toxoid, diphtheria toxoid, CRM197, recombinant diphtheria toxin, OMPC from N. meningitidis, and protein D from H influenzae.
17. The immunogenic composition of claims 12-16 formulated as a vaccine for in vivo administration to the host wherein the individual components of the composition are formulated such that the immunogenicity of individual components is not impaired by other individual components of the composition.
18. The immunogenic composition of claims 12-16 formulated as a vaccine for in vivo administration to the host, which confers an antibody titre superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects.
19. The immunogenic composition of claims 12-18 further comprising an adjuvant.
20. The immunogenic composition of claim 19 wherein the adjuvant is aluminium salts.
21. The multi-valent immunogenic composition of claims 1-9 and 12-20 for use in a medicament.
22. The use of the immunogenic composition of claims 12-20 in the manufacture of a medicament for the treatment or prevention of diseases caused by infection by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis.
23. A method of immunising a human host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae and N. meningitidis, which method comprises administering to the host an immunoprotective dose of the immunogenic composition of claims 12-20.
24. A process for making the multi-valent immunogenic composition of claims 1-9 and 12-20 comprising the step of mixing together the individual components.
25. A multi-valent immunogenic composition comprising killed whole-cell Bordetella pertussis, tetanus toxoid, diphtheria toxoid, and a conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B, wherein the amount of conjugate per 0.5 mL dose of bulk vaccine is 1-8 μg, and the immunogenicity of the conjugate is equivalent or improved over such compositions comprising larger amounts of conjugate.
26. The immunogenic composition of claim 25 wherein the carrier protein used is selected from the group comprising: tetanus toxoid, diphtheria toxoid, CRM197, OMPC from N. meningitidis, and protein D from H. influenzae.
27. The immunogenic composition of claim 25 or 26 wherein the amount of conjugate per 0.5 mL dose of bulk vaccine is 3-6 μg.
28. The immunogenic composition of claim 25 or 26 wherein the amount of conjugate per 0.5 mL dose of bulk vaccine is 5 μg.
29. The immunogenic composition of claims 25-28, wherein the conjugate of a carrier protein and the capsular polysaccharide of H. influenzae type B is not adsorbed onto an aluminium adjuvant salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/439,829 US9233151B2 (en) | 2000-06-29 | 2012-04-04 | Vaccine composition |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0015999.6A GB0015999D0 (en) | 2000-06-29 | 2000-06-29 | Novel compounds |
GB0015999.6 | 2000-06-29 | ||
GB0108363.3 | 2001-04-03 | ||
GBGB0108364.1A GB0108364D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
GB0108363A GB0108363D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
GB0108364.1 | 2001-04-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/439,829 Division US9233151B2 (en) | 2000-06-29 | 2012-04-04 | Vaccine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030180316A1 true US20030180316A1 (en) | 2003-09-25 |
Family
ID=27255788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/312,090 Abandoned US20030180316A1 (en) | 2000-06-29 | 2001-06-27 | Multivalent vaccine composition |
US13/439,829 Expired - Fee Related US9233151B2 (en) | 2000-06-29 | 2012-04-04 | Vaccine composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/439,829 Expired - Fee Related US9233151B2 (en) | 2000-06-29 | 2012-04-04 | Vaccine composition |
Country Status (35)
Country | Link |
---|---|
US (2) | US20030180316A1 (en) |
EP (4) | EP1296715B2 (en) |
JP (2) | JP4870895B2 (en) |
KR (3) | KR100837917B1 (en) |
CN (2) | CN101708333B (en) |
AP (1) | AP1695A (en) |
AT (1) | ATE534402T1 (en) |
AU (2) | AU2001281895C1 (en) |
BG (2) | BG66238B1 (en) |
BR (2) | BRPI0112057B8 (en) |
CA (2) | CA2783274C (en) |
CY (2) | CY1112280T1 (en) |
CZ (1) | CZ20024224A3 (en) |
DK (2) | DK1296715T4 (en) |
DZ (1) | DZ3399A1 (en) |
EA (2) | EA011480B1 (en) |
EG (1) | EG24742A (en) |
ES (2) | ES2385100T3 (en) |
HK (1) | HK1055244A1 (en) |
HU (3) | HU227613B1 (en) |
IL (2) | IL153506A0 (en) |
MA (1) | MA25824A1 (en) |
MX (1) | MXPA03000198A (en) |
MY (1) | MY133981A (en) |
NO (1) | NO332495B1 (en) |
NZ (1) | NZ523319A (en) |
OA (1) | OA12302A (en) |
PE (1) | PE20020126A1 (en) |
PL (2) | PL210015B1 (en) |
PT (2) | PT1296715E (en) |
SI (2) | SI1946769T1 (en) |
SK (1) | SK288007B6 (en) |
UA (2) | UA85853C2 (en) |
UY (1) | UY26801A1 (en) |
WO (1) | WO2002000249A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089794A3 (en) * | 2004-03-15 | 2006-03-09 | Chiron Srl | Combination vaccines with low dose of hib conjugate |
US20060127414A1 (en) * | 2002-11-01 | 2006-06-15 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition |
US20070184071A1 (en) * | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070231340A1 (en) * | 2005-04-08 | 2007-10-04 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20080193476A1 (en) * | 2005-06-27 | 2008-08-14 | Ralph Leon Biemans | Immunogenic Composition |
US20090130137A1 (en) * | 2005-04-08 | 2009-05-21 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20090214586A1 (en) * | 2005-03-17 | 2009-08-27 | Mario Contorni | Combination Vaccines With Whole Cell Pertussis Antigen |
US20090318382A1 (en) * | 2006-06-30 | 2009-12-24 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
US20100034850A1 (en) * | 2006-09-07 | 2010-02-11 | Herve De Hemptinne | Vaccine |
US20100034847A1 (en) * | 2005-09-01 | 2010-02-11 | Astrid Borkowski | Multiple vaccination including Serogroup C Meningococcus |
US20110071279A1 (en) * | 2005-04-08 | 2011-03-24 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20110182942A1 (en) * | 2008-05-30 | 2011-07-28 | Wendell David Zollinger | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
US20110195086A1 (en) * | 2010-02-09 | 2011-08-11 | Caulfield Michael J | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
US20180099039A1 (en) * | 2014-01-21 | 2018-04-12 | Pfizer Inc. | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof |
CN111821432A (en) * | 2020-08-05 | 2020-10-27 | 北京智飞绿竹生物制药有限公司 | Multivalent pneumococcal conjugate vaccine |
US11116828B2 (en) | 2017-12-06 | 2021-09-14 | Merck Sharp & Dohme Corp. | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
US11642406B2 (en) | 2018-12-19 | 2023-05-09 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
US11969474B2 (en) | 2018-05-07 | 2024-04-30 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4540795B2 (en) * | 2000-03-10 | 2010-09-08 | 一般財団法人阪大微生物病研究会 | Method for causing cellular immune activity of live vaccine to occur in inactivated vaccine, and mixed vaccine obtained therefrom |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
MY133981A (en) | 2000-06-29 | 2007-11-30 | Smithkline Beecham Biologicals S A | Vaccine composition |
CN100556459C (en) | 2001-01-23 | 2009-11-04 | 安万特巴斯德公司 | Multivalent meningococcal polysaccharide-protein conjugate vaccines |
AU2007200116A1 (en) * | 2001-04-03 | 2007-02-01 | Glaxosmithkline Biologicals S.A. | Vaccine composition |
DE60236864D1 (en) | 2001-05-31 | 2010-08-12 | Novartis Vaccines & Diagnostic | CHIMERIC ALPHAVIRUS REPLICANT PARTICLES |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
EP1506007B1 (en) * | 2002-05-14 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Mucosal combination vaccines for bacterial meningitis |
MXPA04011249A (en) | 2002-05-14 | 2005-06-06 | Chiron Srl | Mucosal vaccines with chitosan adjuvant and meningococcal antigens. |
JP4697706B2 (en) | 2002-10-11 | 2011-06-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Polypeptide-vaccine for broad protection against highly virulent meningococcal strains |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA3042073C (en) | 2003-01-30 | 2022-09-13 | Novartis Vaccines And Diagnostics S.R.L. | Injectable vaccines against multiple meningococcal serogroups |
JP2006516609A (en) * | 2003-01-30 | 2006-07-06 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Mucosal meningococcal vaccine |
BRPI0410423A (en) | 2003-05-07 | 2006-06-06 | Sanofi Pasteur Inc | improved immunogenicity process for meningococcal vaccination |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
EP2364725A3 (en) * | 2003-06-23 | 2012-05-09 | Sanofi Pasteur Inc. | Immunization method against neisseria meningitidis serogroups a and c |
JP4738339B2 (en) * | 2003-10-02 | 2011-08-03 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Liquid vaccine for multiple meningococcal serogroups |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
CU23404A1 (en) * | 2003-11-19 | 2009-08-04 | Ct Ingenieria Genetica Biotech | NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS |
EP1740217B1 (en) | 2004-04-30 | 2011-06-15 | Novartis Vaccines and Diagnostics S.r.l. | Meningococcal conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
SG175456A1 (en) | 2005-04-18 | 2011-11-28 | Novartis Vaccines & Diagnostic | Expressing hepatitis b virus surface antigen for vaccine preparation |
GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CN1709505B (en) * | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine |
CN101355960A (en) | 2005-10-18 | 2009-01-28 | 诺华疫苗和诊断公司 | Mucosal and systemic immunizations with alphavirus replicon particles |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
KR101515078B1 (en) * | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccines |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP1940462A2 (en) * | 2005-12-23 | 2008-07-09 | GlaxoSmithKline Biologicals S.A. | Conjugate vaccines |
ES2809167T3 (en) * | 2006-01-17 | 2021-03-03 | Forsgren Arne | A novel surface-exposed protein from Haemophilus influenzae (protein E; pE) |
TR201807355T4 (en) | 2006-03-22 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Immunization regimens with meningococcal conjugates. |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
BRPI0810778A2 (en) | 2007-05-02 | 2011-09-13 | Glaxosmithkline Biolog Sa | kit, combined vaccine, and methods of decreasing crm neighborhood interference over a sensitive antigen in a primary immunization schedule of a vaccine, and decreasing neighborhood interference over a sensitive antigen, and use of saccharide conjugates |
ES2555786T3 (en) | 2007-06-04 | 2016-01-08 | Glaxosmithkline Biologicals Sa | Vaccination formulation against meningitis |
ES2552366T3 (en) | 2007-06-26 | 2015-11-27 | Glaxosmithkline Biologicals S.A. | Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
PE20100365A1 (en) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | NEW COMBINATION VACCINES WITH WHOLE CELL COUGH AND METHOD FOR THEIR PREPARATION |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
PT2575870T (en) * | 2010-06-04 | 2017-02-10 | Wyeth Llc | Vaccine formulations |
CN103260642B (en) * | 2010-12-14 | 2018-03-16 | 葛兰素史密丝克莱恩生物有限公司 | Mycobacterial antigen composition |
CN103442730B (en) | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | Combination septivalency vaccine |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
DE102011122891B4 (en) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentation medium, which is free of animal components, for the preparation of diphtheria toxoids for use in the vaccination of humans |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
DE102011118371B4 (en) | 2011-11-11 | 2014-02-13 | Novartis Ag | Composition suitable for human vaccination, comprising a diphtheria toxoid, and process for its preparation |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
SI2809349T1 (en) * | 2012-01-30 | 2019-03-29 | Serum Institute Of India Private Limited | Immunogenic composition |
EP2822584A1 (en) * | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
JP2015525794A (en) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Method for eliciting an immune response against RSV and Bordetella pertussis in infants |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP6440619B2 (en) | 2012-10-12 | 2018-12-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Uncrosslinked acellular pertussis antigen for combination vaccines |
EA201590491A1 (en) * | 2012-10-17 | 2016-01-29 | Глаксосмитклайн Байолоджикалс С.А. | IMMUNOGENIC COMPOSITION |
KR20140075201A (en) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
PE20151720A1 (en) | 2013-03-08 | 2015-12-10 | Crucell Holland Bv | ACELLULAR VACCINE AGAINST PERTUSSIS |
RU2016103771A (en) * | 2013-07-07 | 2017-08-11 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 1 |
EP3492097A1 (en) | 2013-08-05 | 2019-06-05 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
RU2626532C2 (en) * | 2015-01-16 | 2017-07-28 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Combined vaccine to prevent whooping cough, diphtheria, tetanus, hepatitis and infections caused by type b haemophilus influenzae |
MX2017010705A (en) * | 2015-02-19 | 2017-12-04 | Pfizer | Neisseria meningitidis compositions and methods thereof. |
CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2019001342A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
CN109890413B (en) | 2016-09-02 | 2024-04-16 | 赛诺菲巴斯德股份有限公司 | Neisseria meningitidis vaccine |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CA3089007A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2019152921A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP2021522213A (en) | 2018-04-18 | 2021-08-30 | エスケー バイオサイエンス カンパニー リミテッド | Streptococcus pneumoniae capsular polysaccharide and its immunogenic zygotes |
US11896656B2 (en) * | 2018-04-30 | 2024-02-13 | Merck Sharp & Dohme Llc | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
KR20200005458A (en) | 2018-07-06 | 2020-01-15 | 주식회사 유바이오로직스 | Immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate, and phamatiutical composition comprising the same |
KR20210092224A (en) * | 2018-11-10 | 2021-07-23 | 브하라트 바이오테크 인터내셔날 리미티드 | Multivalent Glycoconjugate Immunogenic Composition |
GB2599572B (en) | 2019-05-20 | 2023-09-20 | Soligenix Inc | Compositions and methods of manufacturing trivalent filovirus vaccines |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4365170A (en) * | 1979-09-21 | 1982-12-21 | Hitachi, Ltd. | Semiconductor switch |
US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4650740A (en) * | 1983-09-13 | 1987-03-17 | Fuji Photo Film Co., Ltd. | Heat-sensitive recording material |
US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4709017A (en) * | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US5651971A (en) * | 1993-09-22 | 1997-07-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
US5843711A (en) * | 1992-05-06 | 1998-12-01 | The Regents Of The University Of California | Diphtheria toxin receptor-binding region |
US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US5917017A (en) * | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US6251401B1 (en) * | 1994-11-02 | 2001-06-26 | Chiron S.P.A. | Combined meningitis vaccine |
US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US20030099672A1 (en) * | 2000-03-17 | 2003-05-29 | Dominique Schultz | Pneumococcus polysaccharide conjugates for use as vaccine against tetanus an diphtheria |
US20040096461A1 (en) * | 2002-07-30 | 2004-05-20 | Baxter Healthcare Corporation | Chimeric multivalent polysaccharide conjugate vaccines |
US20040202668A1 (en) * | 2001-04-03 | 2004-10-14 | Dominique Boutriau | Vaccine composition |
US20080199490A1 (en) * | 2005-06-27 | 2008-08-21 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition |
US20080260773A1 (en) * | 2004-12-24 | 2008-10-23 | Giuseppe Del Giudice | Saccharide Conjugate Vaccines |
US20080305127A1 (en) * | 2005-12-23 | 2008-12-11 | Glaxosmithkline Biologicals S.A. | Conjugate Vaccines |
US20090010959A1 (en) * | 2005-12-22 | 2009-01-08 | Ralph Leon Biemans | Pneumococcal Polysaccharide Conjugate Vaccine |
US20090043077A1 (en) * | 2005-02-01 | 2009-02-12 | Francesco Berti | Conjugation of streptococcal capsular saccharides |
US20090162394A1 (en) * | 2006-04-07 | 2009-06-25 | Ralph Leon Biemans | Vaccine |
US20090311285A1 (en) * | 2007-01-04 | 2009-12-17 | Glaxosmith Kline Biologicals S.A. A Corporation | Vaccine |
US20100060945A1 (en) * | 2007-03-14 | 2010-03-11 | Konica Minolta Business Technologies, Inc. | Information embedding method, its program and information embedding device |
US20100074918A1 (en) * | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
US20100104593A1 (en) * | 2005-01-14 | 2010-04-29 | Chiron Srl | Meningococcal conjugate vaccination |
US20100143399A1 (en) * | 2007-01-04 | 2010-06-10 | Glaxosmithkline Biologicals | Process for manufacturing vaccines |
US20100183662A1 (en) * | 2007-06-26 | 2010-07-22 | Ralph Leon Biemans | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
US20100203137A1 (en) * | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
GB8516442D0 (en) | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
EP2289548A3 (en) | 1992-05-23 | 2012-08-08 | GlaxoSmithKline Biologicals S.A. | Combined vaccines comprising hepatitis B surface antigen and other antigens |
JP3428646B2 (en) | 1992-06-18 | 2003-07-22 | プレジデント アンド フェローズ オブ ハーバードカレッジ | Diphtheria toxin vaccine |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
EP0594950B1 (en) * | 1992-10-27 | 1999-01-27 | American Cyanamid Company | Combination pediatric vaccine with enhanced immunogenicity of each vaccine component |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
WO1997000697A1 (en) * | 1995-06-23 | 1997-01-09 | Smithkline Beecham Biologicals S.A. | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
WO1998033923A1 (en) | 1997-01-30 | 1998-08-06 | Imperial College Of Science, Technology & Medicine | MUTANT msbB or htrB GENES |
EP1028750B1 (en) * | 1997-09-15 | 2006-02-01 | Sanofi Pasteur MSD | Method for preparing multivalent vaccines |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
MY133981A (en) | 2000-06-29 | 2007-11-30 | Smithkline Beecham Biologicals S A | Vaccine composition |
GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
-
2001
- 2001-06-27 MY MYPI20013027 patent/MY133981A/en unknown
- 2001-06-27 SK SK1843-2002A patent/SK288007B6/en not_active IP Right Cessation
- 2001-06-27 PL PL360265A patent/PL210015B1/en unknown
- 2001-06-27 AP APAP/P/2002/002700A patent/AP1695A/en active
- 2001-06-27 BR BRPI0112057A patent/BRPI0112057B8/en not_active IP Right Cessation
- 2001-06-27 PT PT01960390T patent/PT1296715E/en unknown
- 2001-06-27 AU AU2001281895A patent/AU2001281895C1/en active Active
- 2001-06-27 SI SI200131012T patent/SI1946769T1/en unknown
- 2001-06-27 ES ES07116669T patent/ES2385100T3/en not_active Expired - Lifetime
- 2001-06-27 CA CA2783274A patent/CA2783274C/en not_active Expired - Lifetime
- 2001-06-27 UY UY26801A patent/UY26801A1/en not_active IP Right Cessation
- 2001-06-27 OA OA1200200395A patent/OA12302A/en unknown
- 2001-06-27 HU HU1000594A patent/HU227613B1/en unknown
- 2001-06-27 EG EG20010701A patent/EG24742A/en active
- 2001-06-27 DK DK01960390.1T patent/DK1296715T4/en active
- 2001-06-27 KR KR1020027017928A patent/KR100837917B1/en active IP Right Grant
- 2001-06-27 SI SI200131007T patent/SI1296715T2/en unknown
- 2001-06-27 MX MXPA03000198A patent/MXPA03000198A/en active IP Right Grant
- 2001-06-27 IL IL15350601A patent/IL153506A0/en unknown
- 2001-06-27 CN CN200910174266.7A patent/CN101708333B/en not_active Expired - Lifetime
- 2001-06-27 HU HU0301413A patent/HU228384B1/en unknown
- 2001-06-27 NZ NZ523319A patent/NZ523319A/en not_active IP Right Cessation
- 2001-06-27 DK DK07116669.8T patent/DK1946769T3/en active
- 2001-06-27 EA EA200501070A patent/EA011480B1/en not_active IP Right Cessation
- 2001-06-27 EP EP01960390.1A patent/EP1296715B2/en not_active Expired - Lifetime
- 2001-06-27 ES ES01960390.1T patent/ES2375704T5/en not_active Expired - Lifetime
- 2001-06-27 KR KR1020087013186A patent/KR100898845B1/en active IP Right Grant
- 2001-06-27 EP EP10178451A patent/EP2277541A1/en not_active Withdrawn
- 2001-06-27 BR BR122012003821A patent/BR122012003821B8/en not_active IP Right Cessation
- 2001-06-27 HU HU1000593A patent/HU227893B1/en unknown
- 2001-06-27 CN CN018146198A patent/CN1449293B/en not_active Expired - Lifetime
- 2001-06-27 AT AT01960390T patent/ATE534402T1/en active
- 2001-06-27 UA UAA200604994A patent/UA85853C2/en unknown
- 2001-06-27 EP EP07116669A patent/EP1946769B1/en not_active Expired - Lifetime
- 2001-06-27 PT PT07116669T patent/PT1946769E/en unknown
- 2001-06-27 JP JP2002505030A patent/JP4870895B2/en not_active Expired - Lifetime
- 2001-06-27 AU AU8189501A patent/AU8189501A/en active Pending
- 2001-06-27 DZ DZ013399A patent/DZ3399A1/en active
- 2001-06-27 PL PL393584A patent/PL393584A1/en unknown
- 2001-06-27 CZ CZ20024224A patent/CZ20024224A3/en not_active IP Right Cessation
- 2001-06-27 PE PE2001000629A patent/PE20020126A1/en not_active Application Discontinuation
- 2001-06-27 UA UA20021210397A patent/UA76952C2/en unknown
- 2001-06-27 EP EP10178449A patent/EP2279748A1/en not_active Withdrawn
- 2001-06-27 KR KR1020077019832A patent/KR20070091698A/en not_active Application Discontinuation
- 2001-06-27 EA EA200201240A patent/EA006313B1/en not_active IP Right Cessation
- 2001-06-27 WO PCT/EP2001/007288 patent/WO2002000249A2/en active IP Right Grant
- 2001-06-27 CA CA2412497A patent/CA2412497C/en not_active Expired - Lifetime
- 2001-06-27 US US10/312,090 patent/US20030180316A1/en not_active Abandoned
-
2002
- 2002-12-17 IL IL153506A patent/IL153506A/en active IP Right Grant
- 2002-12-20 NO NO20026175A patent/NO332495B1/en not_active IP Right Cessation
- 2002-12-26 MA MA26980A patent/MA25824A1/en unknown
- 2002-12-28 BG BG107422A patent/BG66238B1/en active Active
-
2003
- 2003-08-27 HK HK03106153.7A patent/HK1055244A1/en not_active IP Right Cessation
-
2009
- 2009-11-06 BG BG10110518A patent/BG66249B1/en active Active
-
2010
- 2010-03-15 JP JP2010057779A patent/JP5346308B2/en not_active Expired - Lifetime
-
2012
- 2012-01-30 CY CY20121100103T patent/CY1112280T1/en unknown
- 2012-04-04 US US13/439,829 patent/US9233151B2/en not_active Expired - Fee Related
- 2012-06-15 CY CY20121100549T patent/CY1112915T1/en unknown
Patent Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4365170A (en) * | 1979-09-21 | 1982-12-21 | Hitachi, Ltd. | Semiconductor switch |
US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4650740A (en) * | 1983-09-13 | 1987-03-17 | Fuji Photo Film Co., Ltd. | Heat-sensitive recording material |
US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4709017A (en) * | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US5843711A (en) * | 1992-05-06 | 1998-12-01 | The Regents Of The University Of California | Diphtheria toxin receptor-binding region |
US5651971A (en) * | 1993-09-22 | 1997-07-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US5917017A (en) * | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US6251401B1 (en) * | 1994-11-02 | 2001-06-26 | Chiron S.P.A. | Combined meningitis vaccine |
US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US20030099672A1 (en) * | 2000-03-17 | 2003-05-29 | Dominique Schultz | Pneumococcus polysaccharide conjugates for use as vaccine against tetanus an diphtheria |
US20040202668A1 (en) * | 2001-04-03 | 2004-10-14 | Dominique Boutriau | Vaccine composition |
US20040096461A1 (en) * | 2002-07-30 | 2004-05-20 | Baxter Healthcare Corporation | Chimeric multivalent polysaccharide conjugate vaccines |
US20080260773A1 (en) * | 2004-12-24 | 2008-10-23 | Giuseppe Del Giudice | Saccharide Conjugate Vaccines |
US20100104593A1 (en) * | 2005-01-14 | 2010-04-29 | Chiron Srl | Meningococcal conjugate vaccination |
US20090043077A1 (en) * | 2005-02-01 | 2009-02-12 | Francesco Berti | Conjugation of streptococcal capsular saccharides |
US20090136541A1 (en) * | 2005-06-27 | 2009-05-28 | Ralph Leon Biemans | Immunogenic composition |
US20080199490A1 (en) * | 2005-06-27 | 2008-08-21 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition |
US20090252759A1 (en) * | 2005-06-27 | 2009-10-08 | Ralph Leon Biemans | Immunogenic composition |
US20100215686A1 (en) * | 2005-06-27 | 2010-08-26 | Ralph Leon Biemans | Process for Manufacturing Vaccines |
US20090010959A1 (en) * | 2005-12-22 | 2009-01-08 | Ralph Leon Biemans | Pneumococcal Polysaccharide Conjugate Vaccine |
US20090017059A1 (en) * | 2005-12-22 | 2009-01-15 | Glaxosmithkline Biologicals S.A. | Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates |
US20090017072A1 (en) * | 2005-12-22 | 2009-01-15 | Glaxosmithkline Biologicals S.A. | Vaccine |
US20080305127A1 (en) * | 2005-12-23 | 2008-12-11 | Glaxosmithkline Biologicals S.A. | Conjugate Vaccines |
US20090162394A1 (en) * | 2006-04-07 | 2009-06-25 | Ralph Leon Biemans | Vaccine |
US20100143399A1 (en) * | 2007-01-04 | 2010-06-10 | Glaxosmithkline Biologicals | Process for manufacturing vaccines |
US20090311285A1 (en) * | 2007-01-04 | 2009-12-17 | Glaxosmith Kline Biologicals S.A. A Corporation | Vaccine |
US20100060945A1 (en) * | 2007-03-14 | 2010-03-11 | Konica Minolta Business Technologies, Inc. | Information embedding method, its program and information embedding device |
US20100074918A1 (en) * | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
US20100203137A1 (en) * | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
US20100183662A1 (en) * | 2007-06-26 | 2010-07-22 | Ralph Leon Biemans | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
US20100209450A1 (en) * | 2007-06-26 | 2010-08-19 | Ralph Leon Biemans | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127414A1 (en) * | 2002-11-01 | 2006-06-15 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition |
US8409587B2 (en) * | 2002-11-01 | 2013-04-02 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US20090208526A1 (en) * | 2004-03-15 | 2009-08-20 | Mario Contorni | Combination vaccines with low dose of hib conjugate |
US9259460B2 (en) | 2004-03-15 | 2016-02-16 | Glaxosmithkline Biologicals Sa | Combination vaccines with low dose of Hib conjugate |
WO2005089794A3 (en) * | 2004-03-15 | 2006-03-09 | Chiron Srl | Combination vaccines with low dose of hib conjugate |
US8883166B2 (en) * | 2005-03-17 | 2014-11-11 | Novartis Ag | Combination vaccines with whole cell pertussis antigen |
US20090214586A1 (en) * | 2005-03-17 | 2009-08-27 | Mario Contorni | Combination Vaccines With Whole Cell Pertussis Antigen |
US8808708B2 (en) | 2005-04-08 | 2014-08-19 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20090130137A1 (en) * | 2005-04-08 | 2009-05-21 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070184071A1 (en) * | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US9480736B2 (en) | 2005-04-08 | 2016-11-01 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US8895724B2 (en) | 2005-04-08 | 2014-11-25 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US11191830B2 (en) | 2005-04-08 | 2021-12-07 | Wyeth Llc | Process for preparing pneumococcal polysaccharide-protein conjugates |
US10780160B2 (en) | 2005-04-08 | 2020-09-22 | Wyeth Llc | Process for preparing pneumococcal polysaccharide-protein conjugates |
US10716848B2 (en) | 2005-04-08 | 2020-07-21 | Wyeth Llc | Process for preparing pneumococcal polysaccharide-protein conjugates |
US9981045B2 (en) | 2005-04-08 | 2018-05-29 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20100316666A1 (en) * | 2005-04-08 | 2010-12-16 | Wyeth | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
US20110071279A1 (en) * | 2005-04-08 | 2011-03-24 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US8895024B2 (en) | 2005-04-08 | 2014-11-25 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070231340A1 (en) * | 2005-04-08 | 2007-10-04 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20110201791A1 (en) * | 2005-04-08 | 2011-08-18 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US8603484B2 (en) | 2005-04-08 | 2013-12-10 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US9399060B2 (en) | 2005-04-08 | 2016-07-26 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US9981035B2 (en) | 2005-04-08 | 2018-05-29 | Wyeth Llc | Process for preparing pneumococcal polysaccharide-protein conjugates |
US10166287B2 (en) | 2005-06-27 | 2019-01-01 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US20080199490A1 (en) * | 2005-06-27 | 2008-08-21 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition |
US8431136B2 (en) | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
US20090136541A1 (en) * | 2005-06-27 | 2009-05-28 | Ralph Leon Biemans | Immunogenic composition |
US9931397B2 (en) | 2005-06-27 | 2018-04-03 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US9789179B2 (en) | 2005-06-27 | 2017-10-17 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US20080193476A1 (en) * | 2005-06-27 | 2008-08-14 | Ralph Leon Biemans | Immunogenic Composition |
US10245317B2 (en) | 2005-06-27 | 2019-04-02 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US8883163B2 (en) | 2005-06-27 | 2014-11-11 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US20200000911A1 (en) * | 2005-06-27 | 2020-01-02 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US11241495B2 (en) | 2005-06-27 | 2022-02-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US9486515B2 (en) | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US20090252759A1 (en) * | 2005-06-27 | 2009-10-08 | Ralph Leon Biemans | Immunogenic composition |
US20090041802A1 (en) * | 2005-06-27 | 2009-02-12 | Ralph Leon Biemans | Immunogenic composition |
US9358279B2 (en) | 2005-06-27 | 2016-06-07 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US8007807B2 (en) * | 2005-09-01 | 2011-08-30 | Novartis Vaccines And Diagnostics Gmbh | Multiple vaccination including serogroup C meningococcus |
US20100034847A1 (en) * | 2005-09-01 | 2010-02-11 | Astrid Borkowski | Multiple vaccination including Serogroup C Meningococcus |
US8361477B2 (en) | 2005-09-01 | 2013-01-29 | Novartis Vaccines And Diagnostics Gmbh | Multiple vaccination including serogroup C Meningococcus |
US8444992B2 (en) | 2005-09-01 | 2013-05-21 | Novartis Vaccines And Diagnostics Gmbh | Multiple vaccination including serogroup C meningococcus |
US8784826B2 (en) | 2005-09-01 | 2014-07-22 | Novartis Ag | Multiple vaccination including serogroup C meningococcus |
US11167020B2 (en) | 2006-05-08 | 2021-11-09 | Wyeth Llc | Pneumococcal dosing regimen |
US10406220B2 (en) | 2006-05-08 | 2019-09-10 | Wyeth Llc | Pneumococcal dosing regimen |
US9669084B2 (en) | 2006-05-08 | 2017-06-06 | Wyeth Llc | Pneumococcal dosing regimen |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
US20090318382A1 (en) * | 2006-06-30 | 2009-12-24 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
US9603977B2 (en) | 2006-06-30 | 2017-03-28 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
US9603979B2 (en) | 2006-06-30 | 2017-03-28 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
US20100034850A1 (en) * | 2006-09-07 | 2010-02-11 | Herve De Hemptinne | Vaccine |
US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
US8956625B2 (en) * | 2006-09-07 | 2015-02-17 | Glaxosmithkline Biologicals, S.A. | Inactivated polio vaccines |
US20100040647A1 (en) * | 2006-09-07 | 2010-02-18 | Glaxosmithkline Biologicals S.A. | Vaccine |
US9387239B2 (en) | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
US20110182942A1 (en) * | 2008-05-30 | 2011-07-28 | Wendell David Zollinger | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
US20110195086A1 (en) * | 2010-02-09 | 2011-08-11 | Caulfield Michael J | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
US8192746B2 (en) * | 2010-02-09 | 2012-06-05 | Merck Sharp & Dohme Corp. | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20180099039A1 (en) * | 2014-01-21 | 2018-04-12 | Pfizer Inc. | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof |
US11872274B2 (en) | 2014-01-21 | 2024-01-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11116828B2 (en) | 2017-12-06 | 2021-09-14 | Merck Sharp & Dohme Corp. | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
US11850278B2 (en) | 2017-12-06 | 2023-12-26 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
US11969474B2 (en) | 2018-05-07 | 2024-04-30 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US11642406B2 (en) | 2018-12-19 | 2023-05-09 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CN111821432A (en) * | 2020-08-05 | 2020-10-27 | 北京智飞绿竹生物制药有限公司 | Multivalent pneumococcal conjugate vaccine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9233151B2 (en) | Vaccine composition | |
EP1946771B1 (en) | Multivalent vaccine composition | |
AU2001281895A1 (en) | Vaccine Composition | |
AU2010235979A1 (en) | Vaccine composition | |
ZA200300755B (en) | Multivalent vaccine composition. | |
AU2005203302A1 (en) | Vaccine composition | |
AU2002310903A1 (en) | Vaccine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (FORMERLY SMITHKL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOUTRIAU, DOMINIQUE;CAPIAU, CARINE;DESMONS, PIERRE MICHEL;AND OTHERS;REEL/FRAME:013518/0345;SIGNING DATES FROM 20030217 TO 20030227 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |